Biologics CDMO, Wheeler Bio, has successfully raised USD 35 mn in an oversubscribed Series A-1 funding round. The funds will help the company strengthen its biologics’ manufacturing capabilities, such as planning the development of a large-scale facility.

Canadian CDMO, Delpharm, has secured a USD 42 mn investment from the Canadian Government to enhance the production capacity of its injectables manufacturing facility in Montreal, Canada.

Spanish CDMO, Esteve Química, is investing USD 100 mn to expand its U.S. manufacturing capabilities, focusing on increasing production capacity for high potency APIs (HPAPIs) amid increasing market demands for their use.

Innovation, science, and pharmaceutical services partner, Bend Bioscience, is expanding its Gainesville, Georgia facility with the addition of a commercial-scale spray dryer and a Gerteis drug granulation system.

German CDMO, Adragos Pharma, has announced plans to strengthen its presence in Japan by expanding the production capacity of its Kawagoe facility, acquired from Sanofi in 2023. The company plans to increase solid dosage production to one billion tablets, with further investment to reach a two-billion-tablet capacity.

German CDMO, Vetter, has finalized the third expansion phase of its Center for Visual Inspection and Logistics in Ravensburg, Germany, enhancing its capacity for quality control, storage, and logistics for pharmaceutical companies. The updated facility now includes increased storage capabilities for both refrigerated and room-temperature pharmaceuticals, advanced visual inspection systems, and improved logistics processes.

Indian CRDMO, Syngene International has inaugurated its first U.S.-based manufacturing facility in Rockville, Maryland. The 17,000 square-foot cGMP-certified site will strengthen the company’s CDMO capabilities, and focus on biologics manufacturing, including monoclonal antibodies and recombinant proteins for both clinical and commercial-scale production.

API small molecule and antibody-drug conjugate (ADC) manufacturing company, Axplora, has expanded its Le Mans, France, facility with a cutting-edge payload manufacturing workshop. This expansion is part of the France 2030 program to increase commercial revenue by supplying 40% of the world's marketed ADCs and 50-percent of FDA-approved ADCs.

Northern Ireland-based CDMO, Almac Group, has unveiled a USD 83.7mn investment in a 100,000 sq. ft manufacturing facility at its Craigavon headquarters to produce oral treatments across various therapeutic areas that will feature advanced production suites equipped with the latest pharmaceutical manufacturing technology.

German CDMO, Aenova, has announced a USD 22mn investment to upgrade its Bad Aibling, Germany, site. Capacity for its blister packaging lines has been increased to 220 million blisters, annually, whilst a new strip packaging line increased effervescent output to 420 million tablets a year.

Eli Lilly is committing USD 27 bn to build four new manufacturing plants in the United States, to increase domestic production of active pharmaceutical ingredients and injectable therapies.

Advanced drug discovery and development biotech, Eikon Therapeutics, has announced the initial closing of a USD 350 mn Series D funding round, bringing Eikon's total private funding since its 2019 founding to over USD 1.1 bn.

End-to-end CDMO, Enzene, has announced EU GMP certification for its two facilities in Pune, India, to provide commercial-scale microbial and mammalian drug substance supply, and drug product fill/finish and packaging.

CDMO, Bionova Scientific, has opened a 55,000 sq. ft. process development and pilot plant in Fremont, Calif., to enhance early-stage biologics development and support future manufacturing growth and to strengthen the company’s presence in the Bay Area, which generate USD 142 bn annually.

Over the past 18 months, Minnesota-based CDMO Lifecore Biomedical has moved from being a food business to a pure-play sterile injectable fill-finish CDMO. To support its transition, the company announced the installation of a high-speed, GMP-ready five-head isolator filler to double its production capacity and target USD 130 mn revenue for its 2025 fiscal year.

Novartis has inaugurated its first specialized viral vector production facility in Europe, named VIFA One, located in Mengeš, Slovenia. The USD 42 mn investment enhances the company's research and manufacturing capabilities -particularly in cell and gene therapies, and Novartis will also offer contract manufacturing from the site.

Specialty CDMO, Recipharm, has launched a state-of-the-art modular sterile filling system at its facility in Wasserburg, Germany. Operating within a Grade A isolator, the GMP suite is designed for process development, pilot- and clinical-scale supply projects and will support various container types, including pre-filled syringes and liquid vials, with batch capabilities from 500 to 50,000 units.

Supply chain provider, Frontier Scientific Solutions, has commenced full-scale construction of the state-of-the-art cGMP temperature-controlled facility at Wilmington International Airport (ILM), North Carolina.

Novo Holdings, which acquired Catalent for USD 16.5 bn last year, is considering doubling the size of the CDMO, according to Jonathan Levy, the partner who led the deal. While the acquisition primarily secured three fill/finish sites for Novo Nordisk's weight loss and diabetes drugs, Novo Holdings has yet to clarify its plans for Catalent’s broader network.

Multi-industry manufacturer, Jabil, has completed the acquisition of Pharmaceutics International, Inc. (Pii), a CDMO specializing in aseptic filling, lyophilization, and oral solid dose manufacturing, as the company looks to expand its expertise in parenteral drug delivery which includes GLP-1 treatments and manufacturing services.